Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
XMEX 
3 Key Trends That Are Bullish for Recursion Pharmaceuticals Stock
This company stands to benefit from a shifting pharmaceutical industry landscape.
Recursion Pharmaceuticals (RXRX) Beats Stock Market Upswing: What Investors Need to Know
Recursion Pharmaceuticals (RXRX) reachead $6.36 at the closing of the latest trading day, reflecting a +0.47% change compared to its last close.
Cathie Wood Is Betting on This AI Stock: Is It a Buy?
Wood has a stake in this stock, but it's hardly an "all-in" bet.
Down 57% in 2024, Is Recursion Pharmaceuticals a Buy on the Dip?
This clinical-stage drugmaker's AI platform could speed up the development process, but initial results were disappointing.
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers and Imminent Votes of RXRX and EXAI
NEW YORK, NY / ACCESSWIRE / October 11, 2024 / Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) , relating to its proposed merger with Exscientia PLC.
2 Artificial Intelligence Stocks That Could Deliver Explosive Gains
These two AI innovators are reshaping drug discovery and voice technology – find out why Wall Street sees major upside ahead.
Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts
Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $6.11, signifying a -0.97% move from its prior day's close.
Recursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatment
Recursion said it was able to use its AI-enabled drug discovery platform to identify a novel target and move all the way to gaining IND approval in less than 18 months.
Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $6.67, indicating a -1.91% shift from the previous trading day.
Is Recursion Pharmaceuticals Stock a Buy?
Recursion Pharmaceuticals has an exciting approach to developing therapies. The company recently reported positive phase 2 results for one of its products.
Cathie Wood's Stock Shuffle: 1 Stock She's Loving, 1 She's Leaving
Investors either love Cathie Wood or hate her. The founder of the Ark Invest family of exchange-traded funds can either be phenomenally successful or a dismal failure.
Recursion Stock Down Despite Meeting Goal in Brain Disease Study
RXRX plummets on mixed results from the mid-stage study of its lead candidate, REC-994, for treating a rare neurovascular condition.
